IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$8.49 USD
+0.16 (1.92%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $8.49 0.00 (0.00%) 7:04 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
IGM Biosciences, Inc. [IGMS]
Reports for Purchase
Showing records 61 - 80 ( 87 total )
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; IGM-2323 Update; IGM-8444 Clears Critical Dose Level
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Market Risks Appear Mitigated; IGM-2323 Update Near-Term; Raising PT to $114
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM In-Licenses Birinapant For IGM-8444 Combination; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IgM Platform is Impressive but Value Looks Baked In; Downgrading to NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2020 Takeaways - First Response Look at IGM-2323 in NHL
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM-2323''s Efficacy Likely to Improve At Higher Doses; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Additional IGMS-2323 Data Ahead at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IGM-8444 Phase 1 Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ASH Readout Ahead; DR5 Study Set to Initiate
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
A New Dawn in Antibody Therapeutics; Initiating at Buy and $88 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Exploiting Addiction: A Review of Synthetic Lethality in Cancer
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R